Disease · MONDO_0015492
anti-neutrophil cytoplasmic antibody-associated vasculitis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. anti-neutrophil cytoplasmic antibody-associated vasculitis. Diseases, record MONDO_0015492. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015492
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- AAV, ANCA-associated vasculitis, antineutrophil cytoplasmic antibody-associated vasculitis
- Open Targets
Drugs26
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AVACOPAN | CHEMBL3989871 | Small molecule | Approval | FDA and TTD | 7 | 5 | 5 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| AZATHIOPRINE | CHEMBL1542 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 1 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| BELIMUMAB | CHEMBL1789843 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PIOGLITAZONE | CHEMBL595 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 26
See all 26 drugsTargets17
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| EDNRA | Endothelin-1 receptor | 2 | Endothelin receptor ET-A antagonist | Phase 2 | https://conductscience.org/library/genes/1909 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 2 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| C5 | Complement C5 | 1 | Complement C5 inhibitor | Unknown | https://conductscience.org/library/genes/727 | Drugs and targets |
| C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 1 | C5a anaphylatoxin chemotactic receptor antagonist | Approval | https://conductscience.org/library/genes/728 | Drugs and targets |
| DHODH | Dihydroorotate dehydrogenase (quinone), mitochondrial | 1 | Dihydroorotate dehydrogenase inhibitor | Unknown | https://conductscience.org/library/genes/1723 | Drugs and targets |
| HTT | Huntingtin mRNA | 1 | Huntingtin mRNA antisense inhibitor | Unknown | https://conductscience.org/library/genes/3064 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3615 | Drugs and targets |
1 to 10 of 17
See all 17 targetsTrials32
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00987389 | Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis | Phase 3 | 704 | 2020-05-26 | Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA) | PREDNISOLONE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02994927 | A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis | Phase 3 | 331 | 2022-09-09 | ANCA-Associated Vasculitis | AVACOPAN, AZATHIOPRINE, CYCLOPHOSPHAMIDE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01663623 | Belimumab in Remission of VASculitis | Phase 3 | 106 | 2018-04-17 | Vasculitis | AZATHIOPRINE, BELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02222155 | Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis | Phase 2 | 42 | 2023-08-16 | ANCA-associated Vasculitis | AVACOPAN, CYCLOPHOSPHAMIDE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05376319 | PR3-AAV Resilient Remission or PRRR | Phase 2 | 6 | 2024-07-31 | Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis | OBINUTUZUMAB, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06072482 | A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis | Phase 4 | 300 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | AVACOPAN | Its record names the disease | ClinicalTrials.gov | |
| NCT07168161 | BDB-001 Phase III Trial in ANCA-Associated Vasculitis | Phase 3 | 300 | ANCA Associated Vasculitis (AAV) | AZATHIOPRINE, CYCLOPHOSPHAMIDE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06308978 | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Phase 1 | 244 | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis | BENDAMUSTINE, CYCLOPHOSPHAMIDE, FLUDARABINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00307645 | IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis | Phase 3 | 160 | ANCA Associated Systemic Vasculitis Including Wegener's, Granulomatosis and Microscopic Polyangiitis and, Renal Limited Vasculitis | AZATHIOPRINE, MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00430105 | Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides | Phase 2/3 | 160 | ANCA Associated Systemic Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis | CYCLOPHOSPHAMIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 32
See all 32 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Plasma Exchange vs No Plasma Exchange: Number of Participants With Sustained Remission | 200 of 352 | 197 of 352 | 704 | NCT00987389 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: Composite of i) All-cause Mortality or ii) End-stage Renal Disease | 100 of 352 | 109 of 352 | 704 | NCT00987389 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: deaths from any cause | 46 of 352 | 53 of 352 | 704 | NCT00987389 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: serious adverse events | 225 of 352 | 224 of 352 | 704 | NCT00987389 | Trial comparisons |
| Prednisone Group vs Avacopan Group: Number of Subjects With Clinically Significant ECG Changes From Baseline | 8 of 164 | 12 of 166 | 330 | NCT02994927 | Trial comparisons |
| Prednisone Group vs Avacopan Group: deaths from any cause | 4 of 164 | 2 of 166 | 330 | NCT02994927 | Trial comparisons |
| Prednisone Group vs Avacopan Group: serious adverse events | 74 of 164 | 70 of 166 | 330 | NCT02994927 | Trial comparisons |
| Prednisone Group vs Avacopan Group: Number of Subjects Experiencing a Relapse After Previously Achieving BVAS=0 During the Study | 33 of 157 | 16 of 158 | 315 | NCT02994927 | Trial comparisons |
| Belimumab 10 mg/kg vs Placebo: deaths from any cause | 1 of 53 | 0 of 52 | 105 | NCT01663623 | Trial comparisons |
| Belimumab 10 mg/kg vs Placebo: Number of Participants With Major Relapse During the Double-blind Phase of the Study | 1 of 53 | 0 of 52 | 105 | NCT01663623 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials23
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015492
GET https://conductscience.org/api/diseases/v1/MONDO_0015492/drugs?page=2